Biosimilars in oncology: immunogenicity and extrapolation at ESMO 2019 - 0 views
-
ramchintamaneni on 15 Oct 19Biosimilars in oncology: Less than 50% of oncologists were prescribing biosimilars, primarily due to concerns regarding immunogenicity and extrapolation.